Novel targets for drugs in schizophrenia

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Since the discovery of the first antipsychotic drug, chlorpromazine, in the early 1950s, all effective antipsychotic drugs have been found to share the common property of dopamine D2 receptor antagonism. There has been some suggestion that simple D2 receptor antagonism may not confer optimal antipsychotic efficacy. Currently available antipsychotic drugs leave many symptoms of the illness untreated and cause unacceptable side effects. Recent research in schizophrenia suggests a number of potential new non-D2 targets for pharmacotherapy including glutamate, acetylcholine and serotonin neurotransmitter systems. This review summarises the main neurochemical theories of schizophrenia, and, in the light of these, examines possible therapeutic targets for new antipsychotic drugs.
Original languageEnglish
Article numberN/A
Pages (from-to)265-272
Number of pages8
JournalCns & Neurological Disorders-Drug Targets
Issue number4
Publication statusPublished - Aug 2007


  • Animals
  • Antipsychotic Agents
  • Brain Chemistry
  • Dyskinesia, Drug-Induced
  • Glutamic Acid
  • Humans
  • Neurotransmitter Agents
  • Receptors, Cholinergic
  • Receptors, Dopamine
  • Receptors, Serotonin
  • Schizophrenia


Dive into the research topics of 'Novel targets for drugs in schizophrenia'. Together they form a unique fingerprint.

Cite this